DROFENINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H31NO2
Molecular Weight	317.4656
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)CCOC(=O)C(C1CCCCC1)C2=CC=CC=C2

InChI

InChIKey=AGJBLWCLQCKRJP-UHFFFAOYSA-N

InChI=1S/C20H31NO2/c1-3-21(4-2)15-16-23-20(22)19(17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5,7-8,11-12,18-19H,3-4,6,9-10,13-16H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C20H31NO2
Molecular Weight	317.4656
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11360997 | https://www.ncbi.nlm.nih.gov/pubmed/25089200 | https://www.ndrugs.com/?s=spasmo%20cibalgin

Drofenine, product name Spasmo-Cibalgin (Novartis, Oman), is an antispasmodic/anticholinergic agent used for relaxing smooth muscle, treating dysmenorrhea, and relieving pain in the gastrointestinal tract, biliary passages, and urogenital tract. The possible therapeutic effect of drofenine is proposed by its activation of transient receptor potential vanilloid-3 (TRPV3), a member of the TRPV subfamily of TRP ion channels.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Transient receptor potential cation channel subfamily V member 3 12 Target ID: Q8NET8 Gene ID: 162514.0 Gene Symbol: TRPV3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25089200	Agonist 2678

Conditions

Condition	Modality	Highest Phase	Product
Muscle spasm 40 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11360997	Primary	Not Provided 504	Unknown Approved Use Unknown
Dysmenorrhea 9 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25089200	Primary	Not Provided 504	Spasmo Cibalgin Approved Use Unknown
Pain in the gastrointestinal tract, biliary passages, and urogenital tract 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25089200	Primary	Not Provided 504	Spasmo Cibalgin Approved Use Unknown

PubMed

Title	Date	PubMed
Simultaneous determination of hydrochloride salts of adiphenine, diphenhydramine, ethyldiphenacetate, drofenine and promazine by ion-pair HPLC.	1983 Aug	6140928
Inhibition effects of benactyzine and drofenine on human serum butyrylcholinesterase.	2001 Feb 1	11360997
Drofenine: A 2-APB Analogue with Greater Selectivity for Human TRPV3.	2014 Oct	25089200

Sample Use Guides

In Vivo Use Guide

tablet

Route of Administration: Oral

In Vitro Use Guide

Drofenine, was selective for TRPV3 in that activation of TRPA1, M8, V1, V2, and V4, which are known to be activated by the TRPV3 agonists 2-APB and/or carvacrol, was not observed at concentrations up to 1 mmol/L. A detectable change in TRPV3 activity was observed at concentrations as low as 30 μmol/L and increased in a concentration-dependent manner. At concentrations greater than 500 μmol/L, calcium flux exhibited some evidence of TRPV3 independence based on small and comparable responses in both native HEK-293 cells and other TRP channel overexpressing cell lines. The maximum change in cytosolic calcium (ΔF) for drofenine (EC50 = 207 μmol/L) was comparable to the known TRPV3 agonists 2-APB (EC50 = 78 μmol/L) and carvacrol (EC50 = 438 μmol/L).

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:18:47 UTC 2023` Edited by `admin` on `Fri Dec 15 16:18:47 UTC 2023`
Record UNII	4QWV355536
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DROFENINE

Official Name

English

DROFENINE [MI]

Common Name

English

drofenine [INN]

Common Name

English

NSC-757809

Code

English

CYCLOADIPHENINE

Common Name

English

Drofenine [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29704